Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Want to see IN:ERIS full AI Analyst Report?
ERIS Stock Chart & Stats
₹1530.85
₹7.70(0.59%)
At close: 4:00 PM EST
₹1530.85
₹7.70(0.59%)
Day’s Range― - ―
52-Week Range₹1,237.90 - ₹1,909.55
Previous CloseN/A
Volume91.31K
Average Volume (3M)2.07K
Market Cap
₹186.28B
Enterprise Value₹209.12B
Total Cash (Recent Filing)₹839.20M
Total Debt (Recent Filing)₹23.89B
Price to Earnings (P/E)28.6
Beta0.61
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)30.53
Shares Outstanding138,567,260
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)4.54
Price to Sales (P/S)5.67
P/FCF Ratio354.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)51.34
Revenue Forecast (FY)₹36.63B
Bulls Say, Bears Say
Bulls Say
Strong Operating MarginsConsistently high FY2026 margins indicate durable pricing power in branded formulations and structural profitability in chronic therapies. Such margins create a buffer against cost shocks, support reinvestment in sales/brands, and underpin long-term return generation even if revenue growth moderates.
Branded Chronic Portfolio And Physician-led ModelA physician-focused branded portfolio in chronic/lifestyle therapies drives recurring prescriptions and patient stickiness. Entrenched doctor relationships and recurring demand for chronic drugs support stable, predictable revenue streams and make competitive displacement harder over multiple quarters.
Improved Leverage And Solid ROEMaterial deleveraging versus prior years and a ~16% ROE signal better financial flexibility and efficient capital use. Lower leverage reduces refinancing risk and provides headroom for targeted investment or buybacks, supporting sustainable operations and strategic optionality over the medium term.
Bears Say
Weak Free Cash Flow & Cash ConversionA sharp drop in operating cash flow and FCF versus earnings materially weakens cash conversion, raising earnings-quality concerns. Poor cash conversion limits capacity to fund capex, pay dividends or reduce debt without relying on external financing, increasing structural liquidity risk.
Elevated Debt Relative To Historical BaselineAlthough leverage improved from peak levels, total debt is still materially above the company’s historical near-zero baseline. This structurally higher leverage profile raises interest-cost exposure and reduces financial flexibility to pursue investments or absorb shocks over coming quarters.
Margin And Earnings-quality VolatilityObserved margin swings and a sharp normalization after FY2025 suggest earnings are sensitive to mix, one-offs, or pricing shifts. Persistent volatility undermines predictability of cash flow and planning, complicating resource allocation and elevating execution risk for medium-term targets.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1237.90 and its highest was ₹1909.55 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹186.28B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 67 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on May 20, 2026. The company reported ₹11.7 earnings per share for the quarter, beating the consensus estimate of ₹9.425 by ₹2.275.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Annually dividend of ₹7.35 which represents an annual dividend yield of 0.47%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 138,567,260 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹11.7 in its last earnings report, beating expectations of ₹9.425. Following the earnings report the stock price went up 9.134%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi Consumer Healthcare India Limited
―